GentiBio partners with Bristol Myers Squibb for inflammatory bowel diseases therapies

GentiBio, an engineered regulatory T cells (Tregs) company, has entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).

The collaboration brings together GentiBio’s proprietary engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers Squibb’s leadership in cell therapies and immunology.

During the multi-year collaboration, GentiBio will apply its modular engineered Treg platform and scalable manufacturing process to produce stable and disease-specific engineered Tregs against multiple targets. Bristol Myers Squibb will have the right to develop and advance up to three of the resulting programs into clinical trials.

“We are thrilled to collaborate with Bristol Myers Squibb, a global leader in cell therapy and immunology drug development, to bring critically-needed, disease-modifying therapies to IBD patients,” said Adel Nada, M.D., M.S., co-founder and Chief Executive Officer of GentiBio.

“Unlike existing therapies, Tregs have the unique potential to re-establish immune tolerance in autoimmune and inflammatory diseases such as IBD. This strategic collaboration reflects our shared commitment to creating innovative immunotherapies that are designed to be potent, durable, selective and have the potential to significantly shift the standard of care for patients with autoimmune and autoinflammatory diseases.”

IBD is characterized by debilitating and life-threatening chronic inflammation of the gastrointestinal (GI) tract. Current therapies are largely focused on systemic anti-inflammatory agents and broad immunosuppression, which can have adverse effects outside the GI tract.

“Tregs have demonstrated the potential to suppress inflammation and autoimmune dysfunction in a tissue-restricted manner, thus avoiding widespread, and potentially harmful, immune suppression,” said Robert Plenge, M.D., Ph.D., Bristol Myers Squibb senior vice president and head, Immunology, Cardiovascular and Fibrosis Thematic Research Center and head, Translational Medicine. “We are excited to collaborate with GentiBio as we explore creating potentially promising Tregs for patients suffering from IBD.”

Under the terms of the agreement, Bristol Myers Squibb made an undisclosed upfront cash payment to GentiBio. GentiBio is eligible to receive development and sales milestone payments of up to $1.9 billion and royalties.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news